Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Joseph Nkolola and Dan Barouch.
Joseph Nkolola
Connection Strength
3.792
Dan Barouch
  1. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature. 2021 08; 596(7872):423-427.
    View in: PubMed
    Score: 0.238
  2. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021 06 15; 325(23):2370-2380.
    View in: PubMed
    Score: 0.238
  3. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
    View in: PubMed
    Score: 0.237
  4. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
    View in: PubMed
    Score: 0.235
  5. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. J Virol. 2021 Mar 16.
    View in: PubMed
    Score: 0.234
  6. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb; 590(7844):E25.
    View in: PubMed
    Score: 0.232
  7. Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J Virol. 2021 Jan 20.
    View in: PubMed
    Score: 0.231
  8. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020 10; 586(7830):583-588.
    View in: PubMed
    Score: 0.224
  9. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 08 14; 369(6505):806-811.
    View in: PubMed
    Score: 0.221
  10. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 08 14; 369(6505):812-817.
    View in: PubMed
    Score: 0.221
  11. Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018 12; 564(7734):E8.
    View in: PubMed
    Score: 0.199
  12. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018; 13(11):e0205139.
    View in: PubMed
    Score: 0.199
  13. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
    View in: PubMed
    Score: 0.194
  14. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.193
  15. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. J Virol. 2017 10 15; 91(20).
    View in: PubMed
    Score: 0.184
  16. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med. 2017 Sep 20; 9(408).
    View in: PubMed
    Score: 0.184
  17. Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun. 2017 06 05; 8:15740.
    View in: PubMed
    Score: 0.180
  18. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
    View in: PubMed
    Score: 0.056
  19. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.049
  20. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity. 2017 06 20; 46(6):1073-1088.e6.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.